Donepezil might work, if the patient with amnestic mild cognitive impairment is (a little) depressed.
Researchers estimate that 5% to 32% of patients progress from mild cognitive impairment (MCI) to Alzheimer disease, and symptoms of depression and apathy might be predictive of disease progression. To determine whether interventions might delay this course, researchers analyzed study results on 756 patients (mean age, 72) with amnestic MCI (aMCI) randomized to donepezil, vitamin E, or placebo.
Subjects with histories of major depression in the previous 2 years were excluded. The follow-up lasted 3 years. Informants completed the Beck Depression Inventory (BDI); researchers diagnosed depression in 208 participants at baseline (mean BDI score, 13.6 vs. 4.3 in nondepressed participants). Cognitive scores were similar between treatment groups. R…
Reviewing Author
DisclosuresRoyaltiesTextbook of Traumatic Brain Injury, 2nd and 3rd editions
Editorial BoardsUpToDate; Journal of Neuropsychiatry and Clinical Neuroscience
Leadership Positions in Professional SocietiesNorth American Brain Injury Association (Board Member); National Institute on Disability, Independent Living, and Rehabilitation Research (Chair of Data Monitoring Safety Board for study of donepezil on cognition after traumatic brain injury)
DisclosuresRoyaltiesTextbook of Traumatic Brain Injury, 2nd and 3rd editions
Editorial BoardsUpToDate; Journal of Neuropsychiatry and Clinical Neuroscience
Leadership Positions in Professional SocietiesNorth American Brain Injury Association (Board Member); National Institute on Disability, Independent Living, and Rehabilitation Research (Chair of Data Monitoring Safety Board for study of donepezil on cognition after traumatic brain injury)